Her-2高表达转移性胃癌患者在曲妥珠单抗联合PF方案治疗期生活质量观察4例报告并文献复

Observation of initial stage treatment of trastuzumab combined with PF chemotherapy on QOL in the high expression of HER-2 metastatic gastric cancer patients: four cases report and literature review

目的探讨Her-2高表达转移性胃癌患者接受曲妥珠单抗联合化疗治疗期间生活质量的影响。方法应用EORTC QLQ-C30量表、EORTC QLQ-STO22量表、焦虑自评量表(SAS)以及抑郁自评量表(SDS)评测10例初治的Her-2高表达转移性胃癌患者在接受曲妥珠单抗联合PF方案化疗期间生活质量情况。结果治疗早期患者的整体健康和体力状态有所下降,焦虑、抑郁情况比较严重,随着治疗时间的延长焦虑、抑郁情况未有明显改善但整体生活质量却得到一定程度提高。结论在治疗过程中患者会存在不同的影响生活质量的问题,药物治疗的同时对于伴随的心理问题也要及时予以干预才能最大程度的提高患者的生活质量。

Objective To investigate the effects of initial stage treatment of trastuzumab combined with PF treatment of life in the high expression of her-2 metastatic gastric patients. Methods Application of EORTC QLQ-C30、EORTC QLQSTO22、SAS and SDS to evaluate the quality of life of 4 patients with high expression of her-2 metastatic gastric cancer accepted trastuzumab combined with PF treatment. Results The overall health and physical condition of early patients decreased,and anxiety and depression were more severe. Anxiety and depression did not improve significantly but overall quality of life was improved with the continuation of treatment time. Conclusion Patients have different problems that affect the quality of life in the treatment process. Psychological problems require timely intervention to maximize the quality of life of patients during drug therapy.